Connect your AI

Ultragenyx Pharmaceutical RARE Inventories

Inventories at other companies

Eli LillyLLY

$14.49B+56.1%

AmgenAMGN

$6.19B-8.1%

Ionis PharmaceuticalsIONS

$5.56M-51.7%

ModernaMRNA

$117M-12.7%

BridgeBio PharmaBBIO

$32.98M+734%

Catalyst PharmaceuticalCPRX

$34.93M+76.6%

Other financials

Income statement

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ultragenyx Pharmaceutical's inventories?: Ultragenyx Pharmaceutical (RARE) reported inventories of $55M in Q1 2026.
How has Ultragenyx Pharmaceutical's inventories changed year-over-year?: Ultragenyx Pharmaceutical's inventories increased by 19.5% year-over-year, from $46.03M to $55M.
What is the long-term trend for Ultragenyx Pharmaceutical's inventories?: Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's inventories has grown at a 31.9% compound annual growth rate (CAGR), from $13.05M to $52M.
What does inventories mean?: Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.